SV
Savara Inc.
SVRA · NASDAQ
$4.81 -4.75% (-$0.24)
1M -10.43%
Market Cap $1.12B
P/E Ratio -
Div. Yield -
ROE 90.28%
Bulios Fair Price
$3.77
21.6% downside
Current Price
$4.81
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SVRA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
3 /100
Expensive P/B 7.77x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 23.52%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 82.30%
ROE 90.28%
ROA 72.50%
Debt
100 /100
Low Debt/Equity 0.21x
Current ratio 10.13x
Int. coverage N/A
Stability
46 /100
Moderate Beta 0.25x
EPS volatility 17.68%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SVRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Pauls
Employees
70
Headquarters
Yardley
Upcoming events
11 NOV
Earnings
Upcoming earnings report